Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
61Cu-ATSM
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
61Cu-ATSM is a radiopharmaceutical agent used in positron emission tomography (PET) imaging to identify and delineate hypoxic regions within tumors. It consists of the radioisotope copper-61 (61Cu) chelated by the lipophilic ligand diacetyl-bis(N4-methylthiosemicarbazone) (ATSM). The complex is neutral and membrane-permeable, allowing it to diffuse freely into cells. In the presence of oxygen (normoxia), the copper(II) center is reduced to copper(I) but can be re-oxidized and washed out of the cell. However, in hypoxic environments, the reduced copper(I) species remains trapped intracellularly, leading to selective accumulation in hypoxic tissue. This imaging capability is critical for identifying radioresistant tumor zones, predicting treatment outcomes, and guiding biologically targeted radiation therapy in various cancers, including sinonasal tumors, cervical cancer, and lung cancer.
- Other names
- Copper (61Cu) diacetyl-bis(N4-methylthiosemicarbazone)61Cu-labeled ATSMCopper-61 diacetyl-bis(N4-methylthiosemicarbazone)
02
Targets
HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on 61Cu-ATSM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 61Cu-ATSM.